hotspot -WSS

hotspot

author：fashion 2025-09-29 05:30:55 - browse：69219

Adam's take main illustration — Molly Ferguson/STAT

CHICAGO — Something is off about the way Novartis is talking about pelabresib, its newly acquired and costly treatment for myelofibrosis. I suspect the Swiss pharma giant’s previously stated plan to submit a marketing application to the Food and Drug Administration this year has been blocked.

I’m not just speculating wildly. It’s looking increasingly likely that the $3 billion purchase of MorphoSys to acquire pelabresib — a deal pushed hard by top Novartis executive strategist Ronny Gal over some internal dissent — has run into serious trouble just days after the closing.

On Sunday evening, Novartis Chief Medical Officer Shreeram Aradhye, speaking at the company’s ASCO investor event here in Chicago, offered this response to an analyst who asked about pelabresib.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： The story of mRNA: From a loose idea to a tool that may help curb Covid

WSS

The science behind Janet Jackson's pregnancy at 49

Elizabeth Holmes banned from government health programs

How digital therapeutics firms are pivoting after Pear's bankruptcy

Dewpoint Therapeutics lays off staff after losing partnerships

Death of patient in Alzheimer’s trial raises question of possible risks

Why are elite athletes different? Take a look at their microbes

leisure time

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

entertainment

In Memoriam: Notable people who died in 2023

Why we need to separate burnout from moral injury in health care

United colonoscopy coverage change 'may cost lives,' doctors say

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

United colonoscopy coverage change 'may cost lives,' doctors say

Research misconduct: Proposed new rules face resistance

George Santos makes 1st court appearance after pleading not guilty to 13 counts

The battle over the Brookhaven Landfill on Long Island

The high cost of giving birth even with insurance

Readout Newsletter: Merck, J&J, and long Covid

Wikipedia

The science behind Janet Jackson's pregnancy at 49

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

Obesity experts on risks of Wegovy, Ozempic weight loss drugs

The battle over the Brookhaven Landfill on Long Island

Prior authorization will have to move faster under new Biden rule

Think you might have Covid

entertainment

knowledge

focus

hotspot